November 2019 Blog Posts (1)

FDA approves voxelotor for sickle cell disease

On November 25, 2019, the Food and Drug Administration granted accelerated approval to voxelotor (Oxbryta, Global Blood Therapeutics) for adults and pediatric patients 12 years of age and older with sickle cell disease.

The primary efficacy outcome measure was Hb response rate defined as an Hb increase of >1 g/dL from baseline to week 24. The response rate for voxelotor was 51.1% (46/90) compared to 6.5% (6/92) in the placebo group (p<0.0001). Additional efficacy…

Continue

Added by Ade Dotun on November 27, 2019 at 7:01pm — No Comments

Monthly Archives

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

© 2024   Created by Ade Dotun.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service